THE INDIAN VACCINE

MRNA

Covaxin has been developed by Bharat Biotech in collaboration with Indian council of medical research (ICMR)

It is based on a virus strain isolated by National Institute of Virology Pune. Strain transferred to Bharat Biotech on May 9 to develop vaccine candidate

The inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-safety Level 3) High Containment facility in Genome Valley, Hyderabad

Vaccine

CHADOX1-S

Adv-5 vector

Developer

Oxford University, Astrazeneca Cansino/beijing Institute of Biotech Moderna/niaid

UK

US

ICMR in its letter to trial centres laid down a deadline of August 15 for completion of clinical trials. This has led experts to ask

China

How will processes that require weeks of observation for an immune response be collapsed into days? How will approvals from institutional ethics committees – which can take weeks

Country

Trial phase

Phase 2b/3

Phase 2

Phase 2

-- from each of the trial centres be obtained in this short window? How will generation, entry and analysis of data be done in this time period since trials have not even begun yet

Current stage end

July 2021

January 2021

August 2021